Fast track status to lupus drugFebruary 5, 2019
Baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE),has been granted fast-track designation.
Eli Lilly is currently studying two doses of baricitinib in phase 3 SLE trials. Additionally, Lilly is investigating baricitinib as a potential treatment for moderate to severe atopic dermatitis, a serious form of eczema, with Phase 3 results projected to be shared during the first half of 2019.
Baricitinib is approved in over 50 countries globally as Olumiant for the treatment of adults with rheumatoid arthritis
Baricitinib 2 mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumour necrosis factor (TNF) antagonist therapies.
Baricitinib is a once-daily, oral JAK inhibitor for the treatment of rheumatoid arthritis who have had an inadequate response to one or more TNF inhibitor therapies. Olumiant has shown in non-clinical studies greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3, the four known JAK enzymes dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.